Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer

被引：2
|
作者：
Kowalczyk, Lidia [1 ]
Singer, Christian F. [2 ]
Staudigl, Christine [2 ]
Weber, Myriam [2 ]
Farr, Alex [2 ]
机构：
[1] Univ Vet Med, Clin Unit Anesthesiol & Perioperat Intens Care Me, Vienna, Austria
[2] Med Univ Vienna, Dept Obstet & Gynecol, Ctr Breast Hlth, Waehringer Guertel 18-20, A-1090 Vienna, Austria
来源：
BREAST JOURNAL | 2017年 / 23卷 / 03期
关键词：
D O I：
10.1111/tbj.12676
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：352 / 353
页数：2
相关论文
共 50 条
  • [21] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [22] Pertuzumab (Perjeta) for Preoperative Use in HER2-Positive Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1431): : 98 - +
  • [23] Pertuzumab: a step forward in treating HER2-positive breast cancer
    Mavroudis, Dimitrios
    TRANSLATIONAL CANCER RESEARCH, 2012, 1 (02) : 117 - 118
  • [24] Pertuzumab: new hope for patients with HER2-positive breast cancer
    Capelan, M.
    Pugliano, L.
    De Azambuja, E.
    Bozovic, I.
    Saini, K. S.
    Sotiriou, C.
    Loi, S.
    Piccart-Gebhart, M. J.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 273 - 282
  • [25] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
  • [26] Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sallt
    Button, Peter
    Devitt, Bianca
    Forster, Benjamin
    Fox, Peter
    Harold, Michael
    Ketheeswaran, Sahisha
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    CANCER RESEARCH, 2022, 82 (04)
  • [27] Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
    Tian, Tian
    Ye, Jing
    Zhou, Sihai
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 720 - 727
  • [28] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [29] Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (14): : 1416 - 1416
  • [30] Updates in HER2-Positive Metastatic Breast Cancer
    Gadi, V. K.
    Iyengar, Neil
    Isaacs, Claudine
    Kaklamani, Virginia
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
12345